insights_auto
Why is DMYD-B up 2,19%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 0,98
arrow_upward
+2,19%(+0,021) 1D
9 ຕ.ລ., 17 ໂມງ 29 ນາທີ 56 ວິນາທີ GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 0,95
High
SEK 0,99
Low
SEK 0,92
Mkt. cap
148,45 ລ້ານ
Avg. vol.
759,33 ພັນ
Volume
894,92 ພັນ
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
SEK-1,98
Shares outstanding
134,00 ລ້ານ
No. of employees
42
Open
SEK 0,95
High
SEK 0,99
Low
SEK 0,92
Mkt. cap
148,45 ລ້ານ
Avg. vol.
759,33 ພັນ
Volume
894,92 ພັນ
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
SEK-1,98
Shares outstanding
134,00 ລ້ານ
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
4 ຊົ່ວໂມງກ່ອນ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
24/7 Wall St.
·
17 ຊົ່ວໂມງກ່ອນ
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
Investor's Business Daily
·
5 ຊົ່ວໂມງກ່ອນ
Futures: 6 Stocks Near Buy Points; Big Earnings, Inflation Data Due
The Motley Fool
·
7 ຊົ່ວໂມງກ່ອນ
The Nasdaq-100 Has Gained 20% or More 3 Years Running. This Streak Rests on Far Stronger Earnings Than 1999's.
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB